Towerco Valocîme uses Sitetracker to gain operational efficiency and enable the more fair Towerco business model of Valocîme in France and Europe
2.12.2020 10:00:00 EET | Business Wire | Press release
Sitetracker, the global standard for managing high-volume projects for infrastructure owners and operators like Ericsson, British Telecom, Vertical Bridge, and Vodafone/Vantage Towers, is proud to announce their partnership with Towerco Valocîme, an innovative Tower company in France.
The current distribution of the telecoms value chain is strongly unbalanced in favor of towercos. The purpose of Towerco Valocîme's offers is to rebalance in favor of owners and operators. At the end of 2019, more than 1,000 landlords had signed the Towerco Valocîme offers allowing them to increase their income significantly. In 2020, Towerco Valocîme has launched its operator offers to reduce their hosting costs and thus increase their average operating income per site.
“We have created a fair and simple model for towers in France,” said Frédéric Zimer, CEO of Towerco Valocîme. He continued, “We have thousands of landlords and now we are bringing in operators. The key to maintaining our margins is operational efficiency, which is why we choose to run our operations on Sitetracker.“
Sitetracker’s telecom expertise around processes and capabilities for streamlining real-estate, leases, and permitting will help Towerco Valocîme scale. Built on the Salesforce platform, Sitetracker’s easy to use interface will make it easy for Towerco Valocîme to customize the platform to fit their needs.
With industry-leading capabilities such as Trackers, efficient closeout with automated document generation, out-of-the-box reporting and dashboarding, and Sitetracker Mobile, Towerco Valocîme will be able to build their tower business faster, easier, and more efficiently than ever.
“Being operationally efficient is crucial for our business. With Sitetracker, we will track every step of every project, from site acquisition to leasing in one place. More importantly, we will be able to see at a high level, where we can improve,” said Frédéric Zimer. “I believe this will help us continue to change the way towercos operate and scale our business.”
“We are excited to be partnering with innovators like Towerco Valocîme who are making the towerco industry fair balanced,” says David George, VP of EMEA at Sitetracker. “We are humbled to have been chosen to play such a critical role in their growth and look forward to helping them seize the opportunities ahead.”
To learn more about Towerco Valocîme, visit https://valocime.fr/. For more information on Sitetracker, visit www.sitetracker.com.
About Sitetracker
Sitetracker, Inc. powers the successful deployment of critical infrastructure. As the global standard for managing high-volume projects, the Sitetracker Platform enables growth-focused innovators to optimize the entire asset lifecycle. From the field to the C-suite, Sitetracker enables stakeholders to optimize how they plan, deploy, maintain, and grow their capital asset portfolios. Market leaders in the telecommunications, utility, smart cities, and energy industries — such as Ericsson, Fortis, Alphabet, British Telecom, and Vodafone — rely on Sitetracker to manage millions of sites and projects representing over $24 billion of portfolio holdings globally. For more information, visit www.sitetracker.com.
About Towerco Valocîme
The Towerco Valocîme group was created in 2017 by several business leaders with the aim of enhancing the income from land and property assets of asset owners. Through the telecom, real estate and financial skills of the founders and their associates, the Towerco Valocîme company quickly turned to the valuation of sites and infrastructures hosting telecom and broadcast equipment. They were able to bring together a motivated and competent team in all areas of the value chain. The Towerco Valocîme offers, simple and very attractive for landlords (+20 to + 30% of income) allow the Group to quickly develop a significant portfolio in all French departments from 2017 and 2018. During 2019, the Towerco Valocîme Group has been joined by KKR investment fund, the 3rd largest fund in the world by size, offering Towerco Valocîme first-rate financial capacities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005514/en/
Contact information
Eros Argentiero, +44 7760 967335
eargentiero@sitetracker.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom